Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review by Ewa Stawowczyk, Paweł Kawalec

Get full text

US cost–effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health... by Nipun Atreja, Kasper Johannesen, Rupesh Subash, Carina Bektur, Melissa Hagan, Dionne M Hines, Iulia Dunnett, Ewa Stawowczyk

Cost–effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting... by Rupesh Subash, Thomas Strakosch, Michelle Zhang, Melissa Hagan, Elke Dworatzek, Agnes Kisser, Vasileios Vasilopoulos, Chloe Salter, Carissa Dickerso, Ewa Stawowczyk